Gilead Sciences (GILD) PT Raised to $111 at Piper Jaffray Post Q2
Get Alerts GILD Hot Sheet
Rating Summary:
24 Buy, 16 Hold, 2 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $111.00 (from $106.00) following better-than-expected Q2 results and outlook.
Schimmer commented, "Yet again, GILD easily surpassed top/bottom line numbers but contracted LT growth prospects, so EPS beats are still being accompanied by multiple contraction. As GILD increasingly shifts away from "growth" into "value", the challenge will be identifying opportunities to drive outer-year estimates higher and somehow convincing the Street that there is still growth potential. We suspect this will come in a variety of forms (HCV ex-U.S. performance; transition of HIV franchise to new products; positive pipeline readouts; M&A; dividend/growth) which will help GILD grind higher over the year."
The firm raised FY 2014 EPS from $6.32 to $7.79 and FY 2015 EPS from $7.61 to $9.60.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $90.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- Torrid Holdings Inc (CURV) PT Raised to $4.80 at Jefferies
- Jefferies Upgrades Citizen Watch (7762:JP) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Piper Jaffray, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!